SITEMAP
-
News and Events
-
News
-
Terumo Announces European Launch of Biosimilar Using Terumo’s PLAJEX™ Pre-fillable Syringes
-
Terumo Announces Global Expansion into Canadian Market - Opens 58,000 square foot facility in Vaughan, Ontario
-
Novel Intrasaccular Aneurysm Treatment Device Receives FDA PMA Approval
-
Terumo Establishes New Group Identity Institutes "Core Values" to be Shared by All Associates
-
Terumo Enhances Coronary Interventional Product Portfolio By Securing Exclusive Global Rights to Orchestra BioMed’s Virtue® Sirolimus-Eluting Balloon (SEB) through Global Strategic Partnership
-
Terumo and Kikuna Memorial Hospital to Launch AI-tech Research to Improve PCI Procedure
-
Terumo Acquires Aortica Corporation
-
Terumo Establishes "Terumo Group Human Rights Policy"
-
Terumo Supports Gender Diversity and a Culture of Inclusion and Belonging
-
Terumo Responds to the Novel Coronavirus Outbreak in China
-
Terumo Announces Change of Executive Officers
-
Terumo Statement Regarding Production (COVID-19)
-
Terumo Interventional Systems Statement Regarding Production (COVID-19)
-
Terumo Statement on COVID-19
-
Terumo BCT and Marker Therapeutics Received the First Device FDA Emergency Use Authorization (EUA) to Treat Acute Respiratory Failure in COVID-19 Patients
-
Terumo Donates USD 2.4 Million in Cash and Products to Support COVID-19 Pandemic Relief Efforts Worldwide
-
Terumo Announces Receiving European Medicines Agency GMP Certification for the Manufacturing and Filling of Biologics in PLAJEX™ Polymer Pre-fillable Syringes at Yamaguchi Subsidiary’s Plant
-
Terumo Integrates Two R & D Facilities in Silicon Valley to Accelerate Development of Innovative Medical Devices
-
Terumo Announces Shipping Delays for Products from Ashitaka Factory
-
Terumo Acquires China-based Essen Technology To Enter Drug-eluting Stent Market in China
-
Terumo Acquires Large Bore Vascular Closure Device to Expand Its Interventional Access Device Business in the Fast Growing Segment
-
Terumo to Launch the Ultimaster Tansei Drug Eluting Stent in Europe
-
Terumo Interventional Systems Statement Regarding Production (COVID-19)
-
Terumo Pharmaceutical Solutions wins Asia-Pacific Industry Award
-
Terumo Acquires Quirem Medical to Enhance its Interventional Oncology Field
-
Terumo Statement Regarding Media Reports on Japanese Government's Subsidies Project
-
Terumo’s PLAJEX Enters US Markets by Receiving GMP Certification from FDA to Manufacture Biosimilar Hulio
-
Terumo North America Brings Intelligent Enterprise to Life During Worldwide Pandemic
-
Terumo Pharmaceutical Solutions wins Asia-Pacific Industry Award
-
Terumo Creates Global Group Music
-
Terumo Donates $40,000 to Support American Red Cross California Wildfires Relief Efforts
-
Terumo Announces Commercial Launch of the WEB™ in Japan
-
Terumo Enters 100th Anniversary Year
-
Terumo to Establish 'DX Promotion Department' for Accelerating Group-wide Digital Transformation
-
Terumo Announces Change of Directors and Executive Officers
-
Terumo Revises its Full-Year Financial Guidance for FY2020
-
Terumo Signs a Definitive Agreement to Acquire All Assets of Health Outcomes Sciences, Inc.
-
Terumo Donates Additional USD 1 Million to Support the COVID-19 Solidarity Response Fund for WHO - Contributions will Help Bolster Vaccine Equity
-
Innovative therapies combining Terumo Pharmaceutical Solutions SurGuard®3 safety hypodermic needles with disposable syringes to simplify administration and help prevent needlestick injury
-
Terumo Introduces New AZUR™ Vascular Plug and PG Pro™ Peripheral Microcatheter Embolization System
-
Terumo Celebrates 100th Anniversary of Contributing to Society Through Healthcare
-
Terumo Announces 5-Year Growth Strategy (GS26) to Deliver Solutions to 21st Century Healthcare Challenges
-
Terumo Medical Corporation Applauds ACC/AHA/SCAI Decision to Designate Radial Access Class 1, Level of Evidence A
-
Corazon and Terumo Sign Collaboration and Co-Marketing Agreement
-
Terumo Launches New ‘Terumo Medical Care Solutions’ Brand
-
Terumo Unveils “Terumo’s Purpose” to Enhance Joint Value Creation with Diverse Stakeholders
-
Terumo Announces Study Results Underscoring Safety and Efficacy of Radial to Peripheral (R2P) Interventions in Treatment of Complex Lower Extremity Peripheral Artery Disease (PAD)
-
Terumo Announces European Launch of Biosimilar Using Terumo’s PLAJEX™ Pre-fillable Syringes
- Events
-
News
- Customer Service
- Education & Training
- About Terumo Interventional Systems
-
Procedural Solutions
-
Access & Closure
-
Radial Edge
-
Procedure
-
Radial to Coronary
-
Radial to Visceral
-
Radial to Peripheral
-
REACH PVI Clinical Study Results - Radial Access for Navigation to Your Chosen Lesion for Peripheral Vascular Intervention
-
Combatting the Impact of the Pandemic with Radial Interventions
-
The Excellent Safety Profile of Radial Access
-
Radial Access as the Optimal Choice for Peripheral Interventions
-
Adapting Radial from Cardiac to Lower Extremity Interventions
-
A Different Approach to Your Patient Challenges
-
Radial vs Femoral Access for Peripheral Intervention
-
The Impact of Access Site on Patient Quality of Life
-
REACH PVI Clinical Study Results - Radial Access for Navigation to Your Chosen Lesion for Peripheral Vascular Intervention - Redirect
-
Thank You
-
Contact Us
-
REACH PVI Clinical Study Results - Radial Access for Navigation to Your Chosen Lesion for Peripheral Vascular Intervention
-
Radial to Neurovascular
-
Radial to Coronary
-
Business
-
Education
-
TRI 30th Anniversary
-
Procedure
-
ABOUT PERIPHERAL RAPID EXCHANGE SOLUTIONS
- About Coronary Artery Disease
- About Embolization
-
Below the Knee Procedures
-
R2P Portfolio
- R2P Resource Center
-
Access & Closure
-
Products
-
Access
-
GLIDESHEATH™ Hydrophilic Coated Introducer Sheath
-
GLIDESHEATH SLENDER® Hydrophilic Coated Introducer Sheath
-
GLIDESHEATH SLENDER® Tibial Pedal Kit
-
GLIDEACCESS® Micro Accessing Systems
-
PINNACLE®
-
PINNACLE PRECISION ACCESS SYSTEM® Sheath
-
PINNACLE® DESTINATION® Guiding Sheath
-
PINNACLE® R/O II Radiopaque Marker Introducer Sheath
-
PINNACLE® R/O II HIFLO Introducer Sheath
-
PINNACLE® TIF TIP™ Introducer Sheath
- NAGAREᵀᴹ Steerable Sheath
-
GLIDESHEATH™ Hydrophilic Coated Introducer Sheath
- Closure
-
Guidewires
-
GLIDEWIRE® Hydrophilic Coated Guidewire
-
GLIDEWIRE® Baby-J™ Hydrophilic Coated Guidewire
-
GLIDEWIRE® GT Super-Selective Hydrophilic Coated Guidewire
-
GLIDEWIRE® Gold Hydrophilic Coated Guidewire
-
GLIDEWIRE ADVANTAGE® Peripheral Guidewires
-
GLIDEWIRE ADVANTAGE TRACK™ Peripheral Guidewire
-
GLIDEWIRE® TORQUE™ Device
-
RUNTHROUGH® NS Extra Floppy Coronary Guidewire
-
RUNTHROUGH® NS HYPERCOAT™ Coronary Guidewire
-
GLIDEWIRE® Hydrophilic Coated Guidewire
-
Catheters
-
PG Pro™ Peripheral Microcatheter
-
FINECROSS® MG Coronary Micro-Guide Catheter
-
GLIDECATH® Hydrophilic Coated Catheter
-
HEARTRAIL® III Guiding Catheter
-
NAVICROSS® Support Catheters
-
OPTITORQUE® Coronary Diagnostic Catheter
-
PRIORITYONE® Aspiration Catheter
-
PROGREAT® Microcatheters
-
PROGREAT ALPHA™ Peripheral Microcatheter
-
Progreat Lambda
-
PG Pro™ Peripheral Microcatheter
- Embolics
-
Peripheral Intervention Devices
-
CROSPERIO® OTW PTA Balloon Dilatation Catheter
-
CROSPERIO® RX (0.014") PTA Balloon Dilatation Catheter
-
CROSSTELLA® OTW (0.018") PTA Balloon Dilatation Catheter
-
CROSSTELLA® RX (0.018") PTA Balloon Dilatation Catheter
-
METACROSS® OTW (0.035") PTA Balloon Dilatation Catheter
-
METACROSS® RX (0.035") PTA Balloon Dilatation Catheter
-
R2Pᵀᴹ MISAGO®
-
CROSPERIO® OTW PTA Balloon Dilatation Catheter
- Coronary Intervention Devices
-
Radial-to-Peripheral (R2P) Portfolio
-
Product Concept Submission Process
-
Access
-
Disclaimer
-
Privacy Policy
-
Terms of Use
-
Site Map
-
Find your Territory Manager Result
-
Contact
-
Page Not Found
-
Search
- New Product Concept
-
INVESTIGATOR INITIATED SPONSORED RESEARCH
-
Login Page
- Medical Affairs